USP, NIST & NIIMBL Researchers Collaborate to Improve Measurement of Viral Vectors Used in Cutting-Edge Gene Therapy

Published on :

The United States Pharmacopeia (USP), the U.S. Department of Commerce’s National Institute of Standards and Technology (NIST) and The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) have announced a research collaboration to assess analytical methods and develop standards for adeno-associated virus (AAV), an important mechanism for delivering gene therapies.

5 Questions with Ronald T. Piervincenzi, Ph.D., Chief Executive Officer, United States Pharmacopeia

Published on :

“5 Questions With…” is a weekly BioBuzz series where we reach out to interesting people in the BioHealth Capital Region to share a little about themselves, their work, and maybe something completely unrelated. This week we welcome Ronald T. Piervincenzi, Ph.D., Chief Executive Officer, United States Pharmacopeia.

United States Pharmacopeia acquires Pharmatech Associates, Inc. to expand services that help ensure the quality of medicines

Published on :

United States Pharmacopeia (USP), an independent, scientific nonprofit organization, is pleased to announce the acquisition of Pharmatech Associates, Inc. By adding Pharmatech Associates expertise, USP further advances its more than 200-year mission to help ensure access to quality medicines by extending services that assist manufacturers to meet global quality standards across the drug and product lifecycle.

U.S. Pharmacopeia launches suite of resources to detect substandard and falsified COVID-19 treatments

Published on :

The U.S. Pharmacopeia (USP) announced the release of a range of tools and resources to help reduce risks from substandard and falsified COVID-19 treatments, and to assist manufacturers, regulators, and quality control laboratories in helping to ensure quality COVID-19 treatments are being procured, produced, and distributed.

The BioHealth Capital Region, Epicenter of U.S. Regulatory Infrastructure

Published on :

As one of the world’s top bio hubs, the BioHealth Capital Region (BHCR) is rife with life science assets. The region has been at the forefront of the SARS-CoV-2 vaccine race and it is rapidly becoming a center for advanced manufacturing. The BHCR cell and gene therapy ecosystem is thriving, and the area boasts one of the richest and most diverse tapestries of life science talent and workforce development programming. What’s more, Maryland, Washington, DC, and Virginia are home to several dynamic university systems that keep the talent and tech transfer pipeline humming and full.

5 Questions with Natalie McKinney, Industry Programs Director, Biologics, US Pharmacopeia

Published on :

Natalie McKinney is a marketing strategy leader with 15+ years of experience in life sciences and technology organizations. She uses data-driven, customer-centric approaches to gain a deep understanding of dynamic customer needs and drivers. She enjoys leveraging internal and external relationships to build a holistic customer view and gains alignment on high-impact, right-sized product and marketing investments that are timed appropriately for the market.

Phlow Corp. and USP announce strategic alliance focused on Pharmaceutical Continuous Manufacturing to increase supply of essential medicines for U.S. patients

Published on :

Phlow Corp. and USP announce strategic alliance focused on Pharmaceutical Continuous Manufacturing to increase supply of essential medicines for U.S. patients Richmond, VA., February 22, 2021 – Phlow Corp., a public [….]

Meet the Newest Biotech Workforce: A Spotlight on Recent Grads Starting Careers in Biotechnology

Published on :

Meet the Newest Biotech Workforce: A Spotlight on Recent Grads Starting Careers in Biotechnology